| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6091382 | Clinical Gastroenterology and Hepatology | 2014 | 18 Pages |
Abstract
Eight weeks administration of resveratrol did not significantly improve any features of NAFLD, compared with placebo, but it increased hepatic stress, based on observed increases in levels of liver enzymes. Further studies are needed to determine whether agents that are purported to mimic calorie restriction, such as resveratrol, are safe and effective for complications of obesity. Clinical trials registration no: ACTRN12612001135808.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Veronique S. Chachay, Graeme A. Macdonald, Jennifer H. Martin, Jonathan P. Whitehead, Trisha M. O'Moore-Sullivan, Paul Lee, Michael Franklin, Kerenaftali Klein, Paul J. Taylor, Maree Ferguson, Jeff S. Coombes, Gethin P. Thomas, Gary J. Cowin,